Aviso Wealth Management Sells 259 Shares of Gilead Sciences, Inc. (NASDAQ:GILD)

Aviso Wealth Management trimmed its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 7.0% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,421 shares of the biopharmaceutical company’s stock after selling 259 shares during the quarter. Aviso Wealth Management’s holdings in Gilead Sciences were worth $316,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Kingsview Wealth Management LLC lifted its position in shares of Gilead Sciences by 8.9% during the third quarter. Kingsview Wealth Management LLC now owns 19,923 shares of the biopharmaceutical company’s stock worth $1,670,000 after purchasing an additional 1,628 shares in the last quarter. Larson Financial Group LLC lifted its holdings in Gilead Sciences by 79.2% during the 3rd quarter. Larson Financial Group LLC now owns 7,835 shares of the biopharmaceutical company’s stock worth $657,000 after buying an additional 3,464 shares in the last quarter. Independent Advisor Alliance boosted its position in Gilead Sciences by 1.2% in the 3rd quarter. Independent Advisor Alliance now owns 23,730 shares of the biopharmaceutical company’s stock valued at $1,990,000 after buying an additional 270 shares during the last quarter. Truvestments Capital LLC acquired a new stake in shares of Gilead Sciences in the 3rd quarter valued at $126,000. Finally, FMR LLC lifted its stake in shares of Gilead Sciences by 79.4% during the third quarter. FMR LLC now owns 33,162,319 shares of the biopharmaceutical company’s stock valued at $2,780,329,000 after acquiring an additional 14,680,161 shares during the period. Institutional investors and hedge funds own 83.67% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have commented on GILD. Piper Sandler lifted their target price on shares of Gilead Sciences from $105.00 to $110.00 and gave the stock an “overweight” rating in a report on Wednesday, February 12th. Wells Fargo & Company raised their target price on Gilead Sciences from $120.00 to $140.00 and gave the stock an “overweight” rating in a report on Wednesday, March 5th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $80.00 price target on shares of Gilead Sciences in a research report on Wednesday, December 11th. JPMorgan Chase & Co. boosted their price objective on shares of Gilead Sciences from $105.00 to $115.00 and gave the company an “overweight” rating in a report on Wednesday, January 29th. Finally, Royal Bank of Canada increased their target price on shares of Gilead Sciences from $84.00 to $90.00 and gave the stock a “sector perform” rating in a report on Wednesday, February 12th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have assigned a strong buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $104.52.

Insider Activity

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the firm’s stock in a transaction that occurred on Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the transaction, the chief financial officer now directly owns 129,873 shares of the company’s stock, valued at approximately $11,863,898.55. This trade represents a 1.89 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Over the last 90 days, insiders sold 302,785 shares of company stock valued at $30,503,250. 0.16% of the stock is owned by company insiders.

Gilead Sciences Price Performance

NASDAQ:GILD opened at $107.89 on Wednesday. Gilead Sciences, Inc. has a 12-month low of $62.07 and a 12-month high of $119.96. The firm has a market capitalization of $134.36 billion, a price-to-earnings ratio of 291.59, a P/E/G ratio of 0.71 and a beta of 0.21. The stock’s 50 day moving average price is $104.35 and its two-hundred day moving average price is $94.36. The company has a quick ratio of 1.20, a current ratio of 1.50 and a debt-to-equity ratio of 1.24.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings data on Tuesday, February 11th. The biopharmaceutical company reported $1.90 EPS for the quarter, beating the consensus estimate of $1.67 by $0.23. Gilead Sciences had a net margin of 1.67% and a return on equity of 31.63%. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Friday, March 14th will be issued a $0.79 dividend. This represents a $3.16 dividend on an annualized basis and a yield of 2.93%. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. The ex-dividend date is Friday, March 14th. Gilead Sciences’s dividend payout ratio is currently 854.05%.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.